Hoth Therapeutics, Inc.
HOTH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.01 | 0.02 | -0.10 |
| FCF Yield | -146.32% | -172.07% | -100.33% | -82.83% |
| EV / EBITDA | 0.27 | 28.26 | 0.00 | -0.44 |
| Quality | ||||
| ROIC | -118.41% | -86.44% | -206.00% | -139.38% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.85 | 1.04 | 0.82 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 17.39% | 9.87% | 23.23% | -93.74% |
| Safety | ||||
| Net Debt / EBITDA | 0.86 | 60.32 | 0.00 | 0.61 |
| Interest Coverage | 0.00 | 0.00 | -36.23 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -3,795.54 | -2.81 |